Fulgent Genetics, Inc. (NASDAQ:FLGT) reported Q4 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $67.7 million versus the consensus estimate of $59.57 million.
Fulgent Genetics, Inc. (NASDAQ:FLGT) reported Q4 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $67.7 million versus the consensus estimate of $59.57 million.